The Conversation (0)
BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Treatment of Celiac Disease
Nov. 04, 2013 12:11PM PST
Company NewsBioLineRx (NASDAQ: BLRX) announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease. The study is expected to begin by the end of this year.
BioLineRx (NASDAQ: BLRX) announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease. The study is expected to begin by the end of this year.
As quoted in the market news:
Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx, said “BL-7010 is a significant opportunity for us, considering there are no approved treatments for celiac disease and there are very few clinical-stage projects worldwide currently being developed for this disease. We look forward to commencing the Phase 1/2 safety study for BL-7010 by the end of the year, followed by an efficacy study, which we hope to commence in the second half of 2014.”
Click here for the full press release by BioLineRx (NASDAQ: BLRX)